Patterns in public records, tested

FDA & biotech strategies

Strategies built on FDA approvals, drug trials and device filings, each with its honest grade from past tests — including the ones that don't work.

Filtered to FDA & biotech · Clear filters

Browse the strategies

Updated Oct 17

Strategies we test

plus 2 still gathering data

Solid evidence

None yet

beat similar stocks by more than luck

Firing now

of all 23, with an idea open today

A strategy’s big number is its edge over similar stocks in past tests; the smaller line is its average return over the stated hold (monthly strategies show an average month). Weekly Top 10 shows its total tracked return. Hypothetical results — not investment advice.

ThemeAll0 FDA & biotech0

More filters · 1 changed

EvidenceSolid0 Solid or some0 All5

DirectionAll0 Buy0 Sell short0 Buy + sell short0

Selling short uses borrowed shares to try to profit from a falling price.

SortBest edge Most tries Newest idea

No rule has passed the publication check yet — here is what it takes

All strategies

Showing 0 of 23 strategies · solid evidence · FDA & biotech

No strategy matches these filters with that much evidence.

Show every grade · Clear filters

Go deeper

Our track record →The ideas we show, tracked from the day we first show them — misses included.How we test →Each idea is measured against similar stocks over a fixed hold. Here is how the grade works.Combine rules yourself →Mix our strategies in the Strategy Lab and get the same honest grade.Compare strategies →Put two or three side by side: grades, numbers and shared trades.

Hypothetical, not investment advice. Each position is opened at the next trading day’s close after the record became public and held for the stated time. Sell short ideas assume borrowed shares are sold, then bought back to close. Past results do not predict future results.